NCT06916858Active, not recruiting
Prevalence of OSA and Diagnostic Accuracy of Type 3 Home Sleep Test in Difficult-to-treat Asthma
Source: ClinicalTrials.gov · Last updated 25 Jun 2025
Brief summary (registry, in English)
cross sectional cohort study enroll Patients diagnosed with difficult-to-treat asthma, aged over 18 years, and experiencing persistent symptoms as assessed by the Asthma Control Test (ACT) underwent type 1 in-laboratory polysomnography and type 3 HSAT within 1 month apart
- Status (registry)
- Active, not recruiting
- Study type
- Interventional
- Enrollment
- 37 (estimated)
- First submitted
- 7 Feb 2024
- Start date
- 7 Feb 2024
- Primary completion date
- 30 Jun 2024
- Lead sponsor
- Chulalongkorn University
- Diseases
- Asthma
- NCT number
- NCT06916858
What you commit to
- Study type: Interventional
- Planned participants: 37
- From 7 Feb 2024 to the primary completion date, 30 Jun 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with symptoms compatible with other sleep disorders,
- Patients with a history of or current stroke or transient ischemic attack and Other chronic respiratory diseases.
Other
- Patients or volunteers unable to undergo type 1 and type 3 sleep studies,
- Patients diagnosed with obstructive sleep apnea
Who the study is looking for
- difficult-to-treat asthma .
- Patients aged 18 years or older
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Tidarat Somreusean Coordinator of this site? Confirm its status | Bangkok | Thailand | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.